drugset
drugset / Trial / NCT01662648

Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia

NCT01662648 ↗

Phase 3 Completed 1117 enrolled Janssen Pharmaceutica
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the efficacy of flexibly dosed paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) who were previously unsuccessfully treated with other oral antipsychotics.

Timeline

Start
2007-06
Primary completion
2008-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Paliperidone ER Unknown 3 mg Oral
Subject Paliperidone ER Unknown 12 mg Oral

Indications

schizophrenia